Tim D Ahfeldt, PhD Email Tim Ahfeldt
- ASSISTANT PROFESSOR | Neuroscience
- ASSISTANT PROFESSOR | Neurology
Dr. Tim Ahfeldt is an Assistant Professor for Neuroscience. His laboratory carries out translational research using isogenic human pluripotent stem cell models of Parkinson’s Disease (PD) to investigate pathological mechanisms of PD mutations in differentiated midbrain dopaminergic neurons.
Multi-Disciplinary Training Area
Star Family Prize for Excellence in Advising
Derek Bok Award for Distinct Teaching
Aging, Alzheimer's Disease, Developmental Biology, Genetics, Genetics of Movement disorders, Human Genetics and Genetic Disorders, Lysosomes/endosome, Mitochondria, Neuroscience, Parkinson's Disease, Proteomics
We have developed isogenic hPSCs models of complex polygenic diseases, focusing on Parkinson’s disease (PD). Neurodegenerative diseases including PD show a complicated interplay between environment, risk genes specific cell type vulnerability. hPSC isogenic models allow study of disease genes while controlling for genetic background and cell type. Using CRISPR gene editing techniques, we have introduced fluorescent reporters that allow tracking and purification of different neuronal populations. Further we have generated isogenic lines harboring PD causative or associated mutations. We differentiate hPSCs into specific neuronal populations using 3D-spin culture approaches. For example, PD is characterized by the selective vulnerability of nigral midbrain dopaminergic neurons (DANs). Analysis of our PD model through molecular and functional characterization, phenotyping, transcriptomic and proteomic approaches has enabled us to identify novel disease pathways. Our goal is to gain better mechanistic understanding of PD disease pathology to inform new disease modifying therapeutic approaches.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Ahfeldt did not report having any of the following types of financial relationships with industry during 2020 and/or 2021: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.